Thrivent Financial for Lutherans
HIV

Thrivent Financial for Lutherans’s CALYPTE BIOMEDICAL CORP NEW HIV Stock Holding History

Thrivent Financial for Lutherans’s Portfolio HIV Stock Details HIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-40,000
Closed – – 2431
2017
Q3 		$0 Buy
+40,000
New – ﹤0.01% 2503

Thrivent Financial for Lutherans's HIV Position: Q4 2017 in Review

Thrivent Financial for Lutherans sold out of CALYPTE BIOMEDICAL CORP NEW (HIV) in Q4 2017, closing a stake of 40,000 shares.

Thrivent Financial for Lutherans first reported a position in HIV in Q3 2017 and held it in 1 quarter. The position peaked at $0 in Q3 2017. 1 fund tracked by Wall St. Rank holds HIV as of Q4 2017.

  • Thrivent Financial for Lutherans reported no remaining CALYPTE BIOMEDICAL CORP NEW position as of Q4 2017 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 40,000 CALYPTE BIOMEDICAL CORP NEW shares in Q4 2017.
  • Thrivent Financial for Lutherans first reported a position in CALYPTE BIOMEDICAL CORP NEW in Q3 2017 and held it in 1 quarter.
  • Thrivent Financial for Lutherans's CALYPTE BIOMEDICAL CORP NEW position peaked at $0 in Q3 2017.
  • 1 fund tracked by Wall St. Rank held CALYPTE BIOMEDICAL CORP NEW as of Q4 2017.

Based on Thrivent Financial for Lutherans's 13F filing for Q4 2017, filed 14 Feb 2018.